NasdaqGS:IONSBiotechs
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following FDA Priority Review For Zilganersen
Ionis Pharmaceuticals recently announced that the FDA has accepted for Priority Review its New Drug Application for zilganersen, an investigational RNA-targeted therapy for the rare and often fatal neurological disorder Alexander disease, based on a pivotal study showing clinically meaningful stabilization in gait speed and supportive safety data.
This milestone underscores Ionis’s ability to advance antisense oligonucleotide medicines into late-stage regulatory review for ultra-rare...